Patients with relapsed or refractory multiple myeloma should be given individualized treatment based on numerous factors, including biology of the disease and type of relapse. READ MORE

News

Lenalidomide plus dexamethasone more effectively treats newly diagnosed multiple myeloma patients ineligible for stem-cell transplantation, regardless of age, than a triplet of older drugs.

READ MORE

Early treatment with lenalidomide plus dexamethasone delays time to progression in some high-risk patients with smoldering multiple myeloma.

READ MORE

The International Myeloma Foundation (IMF)–the oldest and largest organization dedicated to improving the lives of myeloma patients while working toward a cure–has issued a statement calling a report by the Institute for Clinical and Economic Review (ICER) on the value of myeloma drugs overly simplistic and one that could limit patient access to optimal treatments.

READ MORE

A Draft Evidence Report evaluating the economic outcomes of eight drugs used to treat multiple myeloma (MM) has been issued by the Institute for Clinical and Economic Review (ICER), and it has already drawn criticism from a major drug developer.

READ MORE